Coveram4 mg+5 mg

Coveram is a fixed-dose combination of an ACE inhibitor (perindopril arginine) and a dihydropyridine calcium channel blocker (amlodipine), indicated for:

• Substitution/maintenance therapy for hypertension: Coveram is indicated in patients whose blood pressure is already adequately controlled with perindopril and amlodipine given concurrently as separate tablets at the same dose levels, to simplify their treatment regimen. It is not intended as initial (first-line) therapy.
• Stable coronary heart disease: Coveram is also used as substitution therapy in patients with stable coronary artery disease who are already stabilized on perindopril and amlodipine at equivalent doses, to reduce the risk of cardiovascular events.
• Hypertension not adequately controlled on monotherapy (in formulations/markets where Coveram is approved for initiation): to lower blood pressure in patients who require more than one agent to achieve blood pressure goals.

Coveram lowers blood pressure and, by extension, reduces the risk of stroke and myocardial infarction associated with uncontrolled hypertension. It is not indicated for the initial (first-time) treatment of hypertension in patients not already on both individual components.

Each tablet of Perindopril Arginine + Amlodipine contains two active ingredients:

• Perindopril arginine – an angiotensin-converting enzyme (ACE) inhibitor, commonly available in strengths equivalent to 3.5 mg, 5 mg, 7 mg, 10 mg or 14 mg perindopril arginine (locally marketed strengths commonly combine 4 mg perindopril arginine with amlodipine).
• Amlodipine (as amlodipine besylate/besilate) – a dihydropyridine calcium channel blocker, commonly available as 5 mg or 10 mg.

In Bangladesh, Perindopril Arginine + Amlodipine is commonly available as tablets containing 4 mg perindopril arginine with either 5 mg or 10 mg amlodipine. Strength and combination should always be confirmed on the product label/pack insert, as strengths vary by brand and market.

Coveram is an oral, fixed-dose combination antihypertensive medicine that combines two complementary mechanisms of blood pressure control in a single tablet:

• Perindopril arginine is a long-acting ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium/water retention.
• Amlodipine is a long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle by inhibiting calcium ion influx, producing peripheral and coronary vasodilation.

Combining the two produces additive blood-pressure-lowering effects while amlodipine's vasodilation can offset the compensatory fluid retention sometimes associated with calcium channel blockers alone, and perindopril's RAAS suppression can blunt calcium-channel-blocker-induced reflex effects. Coveram is used once daily as a convenient, simplified regimen for patients already stabilized on the two components separately.

Perindopril Arginine + Amlodipine combines two agents with complementary and additive antihypertensive mechanisms.

Perindopril arginine (ACE inhibitor)

Perindoprilat, the active metabolite of perindopril, inhibits angiotensin-converting enzyme (ACE), which converts angiotensin I to the potent vasoconstrictor angiotensin II. Inhibition of ACE results in decreased angiotensin II, decreased aldosterone secretion, reduced vasoconstriction, and reduced sodium and water retention, leading to lower blood pressure and reduced cardiac afterload.

Amlodipine (dihydropyridine calcium channel blocker)

Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Its predominant effect is on vascular smooth muscle, producing peripheral arterial vasodilation, reduced peripheral vascular resistance, and increased coronary blood flow, without significant negative inotropic effect at usual doses.

Together, Perindopril Arginine + Amlodipine produces a greater reduction in blood pressure than either component alone, through complementary vasodilatory and RAAS-suppressing pathways.

Coveram should be taken:

• By mouth, once daily, as a single dose.
• Preferably in the morning, before a meal, since food may reduce the rate of absorption of perindopril.
• Swallowed whole with a glass of water; the tablet should not be crushed or chewed unless the product labeling specifically allows it.
• At approximately the same time each day to maintain consistent blood levels and blood pressure control.

Do not stop taking Coveram abruptly without consulting a physician, even if blood pressure appears well controlled.

Coveram has clinically significant interactions with the following:

• Potassium-sparing diuretics, potassium supplements, and salt substitutes containing potassium: increased risk of hyperkalemia due to the perindopril component; monitor serum potassium.
• Lithium: ACE inhibitors (including perindopril) can increase serum lithium concentrations and the risk of lithium toxicity; monitor lithium levels closely if co-administration is necessary.
• NSAIDs (including selective COX-2 inhibitors): may reduce the antihypertensive effect of perindopril and increase the risk of renal impairment, particularly in volume-depleted or elderly patients.
• Other antihypertensives and diuretics: additive hypotensive effect; first-dose or symptomatic hypotension is more likely in volume-depleted patients.
• Dual blockade of the renin-angiotensin system (e.g., combining with aliskiren, angiotensin receptor blockers, or another ACE inhibitor): increases the risk of hypotension, hyperkalemia, and renal impairment; concurrent use with aliskiren is contraindicated in patients with diabetes.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may increase amlodipine plasma concentrations, raising the risk of hypotension and peripheral edema.
• Simvastatin: amlodipine increases simvastatin exposure; simvastatin dose should generally be limited to 20 mg daily when co-administered.
• Gold injections: rare reports of nitritoid reactions (flushing, nausea, vomiting, hypotension) with concurrent ACE inhibitor use.

Always inform your physician or pharmacist of all medicines, supplements, and herbal products being taken before starting Coveram.

Side effects of Coveram arise from both its ACE-inhibitor and calcium-channel-blocker components.

Common side effects

• Peripheral edema (swelling of the ankles/feet), the most common adverse effect, related to amlodipine
• Dizziness or lightheadedness
• Headache
• Persistent dry cough (class effect of ACE inhibitors)
• Flushing and palpitations
• Fatigue or tiredness
• Altered taste (dysgeusia)
• Nausea
• Muscle cramps

Less common but serious side effects

• Angioedema of the face, lips, tongue, glottis, or larynx — requires immediate discontinuation and emergency medical attention, especially if there is airway swelling or difficulty breathing (see Precautions and Warnings)
• Significant hypotension, particularly after the first dose or in volume-depleted patients
• Hyperkalemia
• Deterioration of renal function
• Rare hepatic reactions, including cholestatic jaundice
• Rare blood disorders (neutropenia, agranulocytosis)

Patients should seek prompt medical attention for facial/throat swelling, difficulty breathing or swallowing, fainting, or signs of an allergic reaction.

Pregnancy: Coveram is contraindicated in pregnancy. Drugs that act directly on the renin-angiotensin system, such as the perindopril component of Coveram, can cause injury and death to the developing fetus when used during the second and third trimesters. If pregnancy is detected, Coveram should be discontinued as soon as possible and the patient switched to an alternative antihypertensive with an established safety profile in pregnancy, under physician guidance. Women of childbearing potential should be counseled about these risks before starting therapy.

Lactation: It is not known whether perindopril or amlodipine are excreted in human breast milk in clinically significant amounts. Because of the potential for serious adverse effects in nursing infants, Coveram should generally be avoided during breastfeeding, and a decision should be made between discontinuing breastfeeding or discontinuing the medicine, taking into account the importance of treatment to the mother. Use only under close physician supervision if no suitable alternative exists.

Fetal toxicity (boxed warning class effect): Coveram can cause fetal injury and death when used during pregnancy; discontinue as soon as pregnancy is detected (see Pregnancy and Lactation).

Angioedema

Angioedema of the face, lips, tongue, glottis, or larynx has been reported with ACE inhibitors, including the perindopril component of Coveram, and may occur at any time during treatment. If angioedema involves the tongue, glottis, or larynx, or causes airway obstruction, discontinue Coveram immediately and seek emergency medical treatment. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk.

Hypotension

Symptomatic hypotension may occur, particularly after the first dose, in volume- or salt-depleted patients (e.g., those on diuretics, a low-salt diet, dialysis, or with vomiting/diarrhea) and in patients with severe congestive heart failure. Correct volume depletion before initiating therapy where possible, and monitor closely after the first dose and dose increases.

Hyperkalemia

The perindopril component can cause hyperkalemia, especially in patients with renal impairment, diabetes mellitus, or those taking potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes. Monitor serum potassium periodically.

Renal function

Monitor renal function periodically, especially in patients with pre-existing renal impairment, heart failure, or bilateral renal artery stenosis (or stenosis in a solitary kidney), in whom ACE inhibitors can precipitate acute renal failure.

Cough

A persistent, dry, nonproductive cough is a known class effect of ACE inhibitors and may resolve only after discontinuation of Coveram.

Aortic or mitral valve stenosis; hypertrophic cardiomyopathy

As with other vasodilators, Coveram should be used with particular caution in patients with significant aortic stenosis, as excessive reduction of blood pressure and coronary perfusion may occur.

Ischemic heart disease

Rarely, patients (particularly those with severe obstructive coronary artery disease) may develop increased frequency, duration, or severity of angina, or acute myocardial infarction, on starting calcium channel blocker therapy or at the time of dosage increase.

Hepatic impairment

Amlodipine half-life is prolonged in hepatic impairment; use with caution and appropriate dose titration.

Avoid alcohol, as it may enhance the blood-pressure-lowering effect and the risk of dizziness.

Overdose with Coveram may cause marked hypotension, dizziness, fainting, reflex tachycardia (from amlodipine) or bradycardia, shock, electrolyte disturbances (including hyperkalemia), and renal impairment. Excessive vasodilation with profound and potentially prolonged hypotension is the most significant effect and may require extended monitoring due to the long half-life of amlodipine.

In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center right away. Do not attempt to manage an overdose at home. Management is generally supportive and may include intravenous fluids, positioning to support blood pressure, cardiac and electrolyte monitoring, and vasopressor support in a hospital setting if needed; hemodialysis is unlikely to be beneficial for amlodipine due to high protein binding, but may assist in removing perindoprilat.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

The safety and efficacy of Coveram in children and adolescents (below 18 years) have not been established. Use in this population is not recommended.

Elderly (65 years and older)

Coveram can be used in elderly patients; however, dose titration should proceed cautiously and blood pressure should be monitored closely, as elderly patients may be more sensitive to blood-pressure-lowering effects and may have reduced renal function.

Renal impairment

Use with caution; not generally recommended when creatinine clearance is below 30 mL/min. See Dosage and Administration for adjustment guidance.

Hepatic impairment

Use with caution and at the lowest effective dose, with close monitoring, since amlodipine clearance is reduced.

Pregnancy and breastfeeding

Contraindicated in pregnancy; generally avoided during breastfeeding. See Pregnancy and Lactation.

Coveram is intended for long-term, ongoing management of hypertension and/or stable coronary heart disease. It is typically continued indefinitely as maintenance therapy, for as long as the physician determines it is needed to control blood pressure and reduce cardiovascular risk. Treatment should not be stopped or altered without medical advice, as abrupt discontinuation of antihypertensive therapy can lead to a rebound rise in blood pressure. Periodic follow-up is recommended to reassess blood pressure control, renal function, and electrolytes.

Perindopril Arginine + Amlodipine works through two complementary mechanisms:

• Perindopril arginine inhibits angiotensin-converting enzyme, reducing the formation of angiotensin II (a potent vasoconstrictor) and decreasing aldosterone secretion, which together reduce vascular resistance and sodium/water retention.
• Amlodipine blocks the influx of calcium ions through L-type calcium channels in vascular smooth muscle, causing arterial vasodilation and reduced peripheral vascular resistance.

The combined effect is a greater and more sustained reduction in blood pressure than either agent alone.

D (US FDA legacy pregnancy category, for perindopril component/renin-angiotensin system-acting drugs, based on the pre-2015 letter-category system) — contraindicated in pregnancy.

The safety and efficacy of Coveram have not been established in pediatric patients (below 18 years of age). Coveram is not recommended for use in children or adolescents due to a lack of adequate clinical data in this population.